Evaluation of Nanolipoprotein Particles (NLPs) as an in vivo delivery platform

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Fischer, Nicholas O ^a   Weilhammer, Dina R ^a   Dunkle, Alexis ^a   Thomas, Cynthia ^a   Hwang, Mona ^a   Corzett, Michele ^a   Lychak, Cheri ^a   Mayer, Wasima ^a   Urbin, Salustra ^a   Collette, Nicole ^a   Chang, Jiun Chiun ^b   Loots, Gabriela G ^a,b   Rasley, Amy ^a   Blanchette, Craig D ^a  

^a LAWRENCE LIVERMORE NATIONAL LABORATORY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; NANOPARTICLE; SINGLE STRANDED DNA; 1,2-OLEOYLPHOSPHATIDYLCHOLINE; APOLIPOPROTEIN E4; BACTERIAL ANTIGEN; BACTERIAL DNA; BIOMIMETIC MATERIAL; DIMYRISTOYLPHOSPHATIDYLCHOLINE; DRUG CARRIER; FLUORESCENT DYE; LCRV PROTEIN, YERSINIA; PHOSPHATIDYLCHOLINE; PORE FORMING CYTOTOXIC PROTEIN; RECOMBINANT PROTEIN;

ARTICLE; BODY FLUID; CYTOTOXICITY; DRUG DELIVERY SYSTEM; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; LUNG PARENCHYMA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PURIFICATION; WEIGHT REDUCTION; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DRUG STABILITY; ESCHERICHIA COLI; FEMALE; GENETICS; INTRANASAL DRUG ADMINISTRATION; MALE; METABOLISM; MOUSE; PARTICLE SIZE; SYNTHESIS; TISSUE DISTRIBUTION;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIGENS, BACTERIAL; APOLIPOPROTEIN E4; BIOMIMETIC MATERIALS; DIMYRISTOYLPHOSPHATIDYLCHOLINE; DNA, BACTERIAL; DNA, SINGLE-STRANDED; DRUG CARRIERS; DRUG STABILITY; ESCHERICHIA COLI; FEMALE; FLUORESCENT DYES; LIPOPROTEINS, HDL; MALE; MICE; MICE, INBRED BALB C; NANOPARTICLES; PARTICLE SIZE; PHOSPHATIDYLCHOLINES; PORE FORMING CYTOTOXIC PROTEINS; RECOMBINANT PROTEINS; TISSUE DISTRIBUTION;

EID: 84899806300     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0093342     Document Type: Article

References (63)

1. Cho K, Wang X, Nie S, Chen ZG, Shin DM (2008) Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 14: 1310-1316.
2. Mareeva T, Wanjalla C, Schnell MJ, Sykulev Y (2010) A novel composite immunotoxin that suppresses rabies virus production by the infected cells. J Immunol Methods 353: 78-86.
3. Bhatt R, de Vries P, Tulinsky J, Bellamy G, Baker B, et al. (2003) Synthesis and in vivo antitumor activity of poly(l-glutamic acid) conjugates of 20S-camptothecin. J Med Chem 46: 190-193.
4. Kim TY, Kim DW, Chung JY, Shin SG, Kim SC, et al. (2004) Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res 10: 3708-3716.
5. Malik N, Evagorou EG, Duncan R (1999) Dendrimer-platinate: a novel approach to cancer chemotherapy. Anticancer Drugs 10: 767-776.
6. Markman M (2006) Pegylated liposomal doxorubicin in the treatment of cancers of the breast and ovary. Expert Opin Pharmacother 7: 1469-1474.
7. Manchester M, Singh P (2006) Virus-based nanoparticles (VNPs): platform technologies for diagnostic imaging. Adv Drug Deliv Rev 58: 1505-1522.
8. Wu W, Wieckowski S, Pastorin G, Benincasa M, Klumpp C, et al. (2005) Targeted delivery of amphotericin B to cells by using functionalized carbon nanotubes. Angew Chem Int Ed Engl 44: 6358-6362.
9. Cuenca AG, Jiang H, Hochwald SN, Delano M, Cance WG, et al. (2006) Emerging implications of nanotechnology on cancer diagnostics and therapeutics. Cancer 107: 459-466.
10. Chapman MJ (1980) Animal lipoproteins: chemistry, structure, and comparative aspects. J Lipid Res 21: 789-853.
11. Blanchette CD, Law R, Benner WH, Pesavento JB, Cappuccio JA, et al. (2008) Quantifying size distributions of nanolipoprotein particles with single-particle analysis and molecular dynamic simulations. Journal of Lipid Research 49: 1420-1430.
12. Chromy BA, Arroyo E, Blanchette CD, Bench G, Benner H, et al. (2007) Different apolipoproteins impact nanolipoprotein particle formation. Journal of the American Chemical Society 129: 14348-14354.
13. Miyazaki M, Tajima Y, Ishihama Y, Handa T, Nakano M (2013) Effect of phospholipid composition on discoidal HDL formation. Biochim Biophys Acta 1828: 1340-1346.
14. Fischer NO, Blanchette CD, Segelke BW, Corzett M, Chromy BA, et al. (2010) Isolation, characterization, and stability of discretely-sized nanolipoprotein particles assembled with apolipophorin-III. PLoS One 5: e11643.
15. Ma CI, Beckstead JA, Thompson A, Hafiane A, Wang RH, et al. (2012) Tweaking the cholesterol efflux capacity of reconstituted HDL. Biochem Cell Biol 90: 636-645.
16. Toledo JD, Cabaleiro LV, Garda HA, Gonzalez MC (2012) Effect of reconstituted discoidal high-density lipoproteins on lipid mobilization in RAW 264.7 and CHOK1 cells. J Cell Biochem 113: 1208-1216.
17. Hoang A, Drew BG, Low H, Remaley AT, Nestel P, et al. (2012) Mechanism of cholesterol efflux in humans after infusion of reconstituted high-density lipoprotein. Eur Heart J 33: 657-665.
18. Nestler JE, Bamberger M, Rothblat GH, Strauss JF, 3rd (1985) Metabolism of high density lipoproteins reconstituted with [3H]cholesteryl ester and [14C]cholesterol in the rat, with special reference to the ovary. Endocrinology 117: 502-510.
19. Baylon JL, Lenov IL, Sligar SG, Tajkhorshid E (2013) Characterizing the Membrane-Bound State of Cytochrome P450 3A4: Structure, Depth of Insertion, and Orientation. J Am Chem Soc 135: 8542-8551.
20. Justesen BH, Laursen T, Weber G, Fuglsang AT, Moller BL, et al. (2013) Isolation of monodisperse nanodisc-reconstituted membrane proteins using free flow electrophoresis. Anal Chem 85: 3497-3500.
21. Wadsater M, Laursen T, Singha A, Hatzakis NS, Stamou D, et al. (2012) Monitoring shifts in the conformation equilibrium of the membrane protein cytochrome P450 reductase (POR) in nanodiscs. J Biol Chem 287: 34596-34603.
22. Blanchette CD, Cappuccio JA, Kuhn EA, Segelke BW, Benner WH, et al. (2009) Atomic force microscopy differentiates discrete size distributions between membrane protein containing and empty nanolipoprotein particles. Biochim Biophys Acta 1788: 724-731.
23. Cappuccio JA, Blanchette CD, Sulchek TA, Arroyo ES, Kralj JM, et al. (2008) Cell-free co-expression of functional membrane proteins and apolipoprotein, forming soluble nanolipoprotein particles. Mol Cell Proteomics 7: 2246-2253.
24. Cappuccio JA, Hinz AK, Kuhn EA, Fletcher JE, Arroyo ES, et al. (2009) Cell-free expression for nanolipoprotein particles: building a high-throughput membrane protein solubility platform. Methods Mol Biol 498: 273-296.
25. Tufteland M, Ren G, Ryan RO (2008) Nanodisks derived from amphotericin B lipid complex. J Pharm Sci 97: 4425-4432.
26. Yuan Y, Wang W, Wang B, Zhu H, Zhang B, et al. (2013) Delivery of hydrophilic drug doxorubicin hydrochloride-targeted liver using apoAI as carrier. J Drug Target 21: 367-374.
27. Ding Y, Wang W, Feng M, Wang Y, Zhou J, et al. (2012) A biomimetic nanovector-mediated targeted cholesterol-conjugated siRNA delivery for tumor gene therapy. Biomaterials 33: 8893-8905.
28. Gaidukov L, Bar D, Yacobson S, Naftali E, Kaufman O, et al. (2009) In vivo administration of BL-3050: highly stable engineered PON1-HDL complexes. BMC Clin Pharmacol 9: 18.
29. Frias JC, Ma Y, Williams KJ, Fayad ZA, Fisher EA (2006) Properties of a versatile nanoparticle platform contrast agent to image and characterize atherosclerotic plaques by magnetic resonance imaging. Nano Lett 6: 2220-2224.
30. Fischer NO, Rasley A, Corzett M, Hwang MH, Hoeprich PD, et al. (2013) Colocalized delivery of adjuvant and antigen using nanolipoprotein particles enhances the immune response to recombinant antigens. J Am Chem Soc 135: 2044-2047.
31. Bhattacharya P, Grimme S, Ganesh B, Gopisetty A, Sheng JR, et al. (2010) Nanodisc-incorporated hemagglutinin provides protective immunity against influenza virus infection. J Virol 84: 361-371.
32. Fischer NO, Infante E, Ishikawa T, Blanchette CD, Bourne N, et al. (2010) Conjugation to nickel-chelating nanolipoprotein particles increases the potency and efficacy of subunit vaccines to prevent West Nile encephalitis. Bioconjug Chem 21: 1018-1022.
33. Weilhammer DR, Blanchette CD, Fischer NO, Alam S, Loots GG, et al. (2013) The use of nanolipoprotein particles to enhance the immunostimulatory properties of innate immune agonists against lethal influenza challenge. Biomaterials 34: 10305-10318.
34. Fischer NO, Blanchette CD, Chromy BA, Kuhn EA, Segelke BW, et al. (2009) Immobilization of His-tagged proteins on nickel-chelating nanolipoprotein particles. Bioconjug Chem 20: 460-465.
35. Rensen PC, de Vrueh RL, Kuiper J, Bijsterbosch MK, Biessen EA, et al. (2001) Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting. Adv Drug Deliv Rev 47: 251-276.
36. Chromy BA, Arroyo E, Blanchette CD, Bench G, Benner H, et al. (2007) Different apolipoproteins impact nanolipoprotein particle formation. J Am Chem Soc 129: 14348-14354.
37. Blanchette CD, Fischer NO, Corzett M, Bench G, Hoeprich PD (2010) Kinetic analysis of his-tagged protein binding to nickel-chelating nanolipoprotein particles. Bioconjug Chem 21: 1321-1330.
38. Blanchette CD, Law R, Benner WH, Pesavento JB, Cappuccio JA, et al. (2008) Quantifying size distributions of nanolipoprotein particles with single-particle analysis and molecular dynamic simulations. J Lipid Res 49: 1420-1430.
39. Rollett A, Reiter T, Nogueira P, Cardinale M, Loureiro A, et al. (2012) Folic acid-functionalized human serum albumin nanocapsules for targeted drug delivery to chronically activated macrophages. Int J Pharm 427: 460-466.
40. Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, et al. (1994) Biodegradable long-circulating polymeric nanospheres. Science 263: 1600-1603.
41. Nguyen CA, Allemann E, Schwach G, Doelker E, Gurny R (2003) Cell interaction studies of PLA-MePEG nanoparticles. Int J Pharm 254: 69-72.
42. Lynch I, Cedervall T, Lundqvist M, Cabaleiro-Lago C, Linse S, et al. (2007) The nanoparticle-protein complex as a biological entity; a complex fluids and surface science challenge for the 21st century. Adv Colloid Interface Sci 134-135: 167-174.
43. Salvati A, Pitek AS, Monopoli MP, Prapainop K, Bombelli FB, et al. (2013) Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat Nanotechnol 8: 137-143.
44. Gao T, Blanchette CD, He W, Bourguet F, Ly S, et al. (2011) Characterizing diffusion dynamics of a membrane protein associated with nanolipoproteins using fluorescence correlation spectroscopy. Protein Sci 20: 437-447.
45. Lattuada M, Hatton TA (2007) Functionalization of monodisperse magnetic nanoparticles. Langmuir 23: 2158-2168.
46. Corbierre MK, Cameron NS, Lennox RB (2004) Polymer-stabilized gold nanoparticles with high grafting densities. Langmuir 20: 2867-2873.
47. Jia H, Titmuss S (2009) Polymer-functionalized nanoparticles: from stealth viruses to biocompatible quantum dots. Nanomedicine (Lond) 4: 951-966.
48. Ackermann L, Potukuchi HK, Landsberg D, Vicente R (2008) Copper-catalyzed "click" reaction/direct arylation sequence: modular syntheses of 1,2,3-triazoles. Org Lett 10: 3081-3084.
49. Karver MR, Weissleder R, Hilderbrand SA (2012) Bioorthogonal reaction pairs enable simultaneous, selective, multi-target imaging. Angew Chem Int Ed Engl 51: 920-922.
50. Simon M, Zangemeister-Wittke U, Pluckthun A (2012) Facile double-functionalization of designed ankyrin repeat proteins using click and thiol chemistries. Bioconjug Chem 23: 279-286.
51. Zhang P, Liu S, Gao D, Hu D, Gong P, et al. (2012) Click-Functionalized Compact Quantum Dots Protected by Multidentate-Imidazole Ligands: Conjugation-Ready Nanotags for Living-Virus Labeling and Imaging. Journal of the American Chemical Society.
52. Trang P, Weidhaas JB, Slack FJ (2008) MicroRNAs as potential cancer therapeutics. Oncogene 27 Suppl 2: S52-57.
53. Goodman CM, McCusker CD, Yilmaz T, Rotello VM (2004) Toxicity of gold nanoparticles functionalized with cationic and anionic side chains. Bioconjug Chem 15: 897-900.
54. Murphy CJ, Gole AM, Stone JW, Sisco PN, Alkilany AM, et al. (2008) Gold nanoparticles in biology: beyond toxicity to cellular imaging. Acc Chem Res 41: 1721-1730.
55. Chen HT, Neerman MF, Parrish AR, Simanek EE (2004) Cytotoxicity, hemolysis, and acute in vivo toxicity of dendrimers based on melamine, candidate vehicles for drug delivery. Journal of the American Chemical Society 126: 10044-10048.
56. Fotakis G, Timbrell JA (2006) In vitro cytotoxicity assays: comparison of LDH, neutral red, MTT and protein assay in hepatoma cell lines following exposure to cadmium chloride. Toxicol Lett 160: 171-177.
57. Rubin EM, Ishida BY, Clift SM, Krauss RM (1991) Expression of human apolipoprotein A-I in transgenic mice results in reduced plasma levels of murine apolipoprotein A-I and the appearance of two new high density lipoprotein size subclasses. Proc Natl Acad Sci U S A 88: 434-438.
58. Ziv O, Avtalion RR, Margel S (2008) Immunogenicity of bioactive magnetic nanoparticles: natural and acquired antibodies. J Biomed Mater Res A 85: 1011-1021.
59. Ochsenbein AF, Zinkernagel RM (2000) Natural antibodies and complement link innate and acquired immunity. Immunol Today 21: 624-630.
60. Irngartinger M, Camuglia V, Damm M, Goede J, Frijlink HW (2004) Pulmonary delivery of therapeutic peptides via dry powder inhalation: effects of micronisation and manufacturing. Eur J Pharm Biopharm 58: 7-14.
61. Courrier HM, Butz N, Vandamme TF (2002) Pulmonary drug delivery systems: recent developments and prospects. Crit Rev Ther Drug Carrier Syst 19: 425-498.
62. Azarmi S, Roa WH, Lobenberg R (2008) Targeted delivery of nanoparticles for the treatment of lung diseases. Adv Drug Deliv Rev 60: 863-875.
63. Niven RW (1995) Delivery of biotherapeutics by inhalation aerosol. Crit Rev Ther Drug Carrier Syst 12: 151-231.